| Name | Title | Contact Details |
|---|---|---|
Daren Osato |
Director of Assay Development, RandD | Profile |
We make employer mental health benefits easily accessible. Request a demo today.
Founded in 2019, Engrail is supported by a long-term capital commitment from Nan Fung Life Sciences (NFLS).
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
Craft Health is a pharmaceutical drug delivery company that uses 3D printing technology to create personalized medicines and supplements for its customers.
Digestive Care Inc is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.